接受阿立哌唑或标准治疗的社区精神分裂症患者报告的生活质量和治疗选择倾向:来自STAR研究的结果

Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: Results from the STAR study
2014-04-28 12:26发表评论
期刊: European Psychiatry2008年8月5期23卷

Objective
To evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (SOC).
 
Method
This open-label, 26-week, multi-centre, randomised study compared aripiprazole with SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. The outcome research variables included the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), and the EuroQoL-5D (EQ-5D). The results from these outcome research variables are the focus of this paper addressing quality of life and patient preference.
 
Results
A total of 555 patients were randomised to receive aripiprazole (n = 284) or SOC (n = 271). The OC data at Week 26, reported that more respondents rated the study medication as ‘much better’ compared with their previous medication in the aripiprazole group versus SOC for patients (59% vs 35%, P < 0.001) and caregivers (58% vs 30%, P = 0.014). The improvement in QLS total score was also significantly greater in the aripiprazole group compared with SOC – mean change from baseline in QLS total score of 16.21 vs 10.01 (P < 0.001) at Week 26 (OC data set). A greater proportion of patients (93% vs 85%; P = 0.005) in the aripiprazole group had a satisfactory response on the EQ-5D Self Care Scale; all other EQ-5D scores were similar.
 
Conclusion
The study findings suggest that quality of life and patient medication preference measures were better for aripiprazole than for SOC.
结论:与当前的标准治疗手段相比,阿立哌唑对于患者生活质量的改善更佳,且有更高比例的患者愿意接受阿立哌唑治疗。

学科代码:神经病学 精神病学   关键词:精神分裂症患者 ,全球精选文摘 爱思唯尔医学网, Elseviermed
来源: 爱思唯尔
爱思唯尔介绍:全球最大的科技医学出版商――爱思唯尔以出版发行高品质的、前沿的科学、技术和医学信息,并保证其满足全世界科技和医学工作者对于信息的需求而著称。现在,公司建立起全球的学术体系,拥有7,000名期刊编辑、70,000名编辑委员会成员、200,000专家审稿人以及500,000名作者,每年出版2,000本期刊和2,200种新书,并拥有17,000种在库图书。 马上访问爱思唯尔网站http://www.elseviermed.cn
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录